Abstract:Obstructive sleep apnoea (OSA) is characterised by partial or complete upper airway obstruction during sleep. Approximately 1% to 4% of children are affected by OSA, with adenotonsillar hypertrophy being the most common underlying risk factor. Surgical removal of enlarged adenoids or tonsils is the currently recommended first‐line treatment for OSA due to adenotonsillar hypertrophy. Given the perioperative risk and an estimated recurrence rate of up to 20% following surgery, there has recently been an increased interest in less invasive alternatives to adenotonsillectomy. As the enlarged adenoids and tonsils consist of hypertrophied lymphoid tissue, anti‐inflammatory drugs have been proposed as a potential non‐surgical treatment option in children with OSA. To assess the efficacy and safety of anti‐inflammatory drugs for the treatment of OSA in children. We identified trials from searches of the Cochrane Airways Group Specialised Register, CENTRAL and MEDLINE (1950 to 2019). For identification of ongoing clinical trials, we searched ClinicalTrials.gov and the World Health Organization (WHO) trials portal. Randomised controlled trials (RCTs) comparing anti‐inflammatory drugs against placebo in children between one and 16 years with objectively diagnosed OSA (apnoea/hypopnoea index (AHI) ≥ 1 per hour). Two authors independently performed screening, data extraction, and quality assessment. We separately pooled results for the comparisons 'intranasal steroids' and 'montelukast' against placebo using random‐effects models. The primary outcomes for this review were AHI and serious adverse events. Secondary outcomes included the respiratory disturbance index, desaturation index, respiratory arousal index, nadir arterial oxygen saturation, mean arterial oxygen saturation, avoidance of surgical treatment for OSA, clinical symptom score, tonsillar size, and adverse events. We included five trials with a total of 240 children aged one to 18 years with mild to moderate OSA (AHI 1 to 30 per hour). All trials were performed in specialised sleep medicine clinics at tertiary care centres. Follow‐up time ranged from six weeks to four months. Three RCTs (n = 137) compared intranasal steroids against placebo; two RCTs compared oral montelukast against placebo (n = 103). We excluded one trial from the meta‐analysis since the patients were not analysed as randomised. We also had concerns about selective reporting in another trial. We are uncertain about the difference in AHI (MD −3.18, 95% CI −8.70 to 2.35) between children receiving intranasal corticosteroids compared to placebo (2 studies, 75 participants; low‐certainty evidence). In contrast, children receiving oral montelukast had a lower AHI (MD −3.41, 95% CI −5.36 to −1.45) compared to those in the placebo group (2 studies, 103 participants; moderate‐certainty evidence). We are uncertain whether the secondary outcomes are different between children receiving intranasal corticosteroids compared to placebo: desaturation index (MD −2.12, 95% CI −4.27 to 0.04; 2 studies, 75 participants; moderate‐certainty evidence), respiratory arousal index (MD −0.71, 95% CI −6.25 to 4.83; 2 studies, 75 participants; low‐certainty evidence), and nadir oxygen saturation (MD 0.59%, 95% CI −1.09 to 2.27; 2 studies, 75 participants; moderate‐certainty evidence). Children receiving oral montelukast had a lower respiratory arousal index (MD −2.89, 95% CI −4.68 to −1.10; 2 studies, 103 participants; moderate‐certainty evidence) and nadir of oxygen saturation (MD 4.07, 95% CI 2.27 to 5.88; 2 studies, 103 participants; high‐certainty evidence) compared to those in the placebo group. We are uncertain, however, about the difference in desaturation index (MD −2.50, 95% CI −5.53 to 0.54; 2 studies, 103 participants; low‐certainty evidence) between the montelukast and placebo group. Adverse events were assessed and reported in all trials and were rare, of minor nature (e.g. nasal bleeding), and evenly distributed between study groups. No study examined the avoidance of surgical treatment for OSA as an outcome. There is insufficient evidence for the efficacy of intranasal corticosteroids for the treatment of OSA in children; they may have short‐term beneficial effects on the desaturation index and oxygen saturation in children with mild to moderate OSA but the certainty of the benefit on the primary outcome AHI, as well as the respiratory arousal index, was low due to imprecision of the estimates and heterogeneity between studies. Montelukast has short‐term beneficial treatment effects for OSA in otherwise healthy, non‐obese, surgically untreated children (moderate certainty for primary outcome and moderate and high certainty, respectively, for two secondary outcomes) by significantly reducing the number of apnoeas, hypopnoeas, and respiratory arousals during sleep. In addition, montelukast was well tolerated in the children studied. The clinic -Abstract Truncated-

The combination of nasal steroids and anti-leukotriene to reduce adenectomy in children with OSA and adenoid hypertrophy

Efficacy of montelukast for adenoid hypertrophy in paediatrics: A systematic review and meta‐analysis

Efficacy of obstructive sleep apnea treatment by antileukotriene receptor and surgery therapy in children with adenotonsillar hypertrophy: A descriptive and cohort study

Novel Classification System of Adenoids Based on Appearance and Its Relationship with Drug Therapy

Effectiveness of Adenoidectomy as a Standalone Procedure in Improving the Quality of Life of Children with Obstructive Sleep Apnea

Anti-inflammatory medications for obstructive sleep apnoea in children.

Association of allergic rhinitis with persistent obstructive sleep apnea: A secondary analysis of the childhood adenotonsillectomy trial

EFFECT OF ENLARGED ADENOIDS AND TONSILS ON BLOOD OXYGEN SATURATION IN AL BAHA, SAUDI ARABIA

[Correlation between allergic rhinitis and childhood obstructive sleep apnea-hypopnea syndrome].

Effective treatment of a child with adenoidal hypertrophy and severe asthma by omalizumab: a case report

Th17/Treg balance in children with obstructive sleep apnea syndrome and the relationship with allergic rhinitis

Persistent Obstructive Sleep Apnea Post-adenotonsillectomy in Children

Maximal medical treatment of adenoid hypertrophy: a prospective study of preschool children

An Objective Study to Establish Incidence of True Obstructive Sleep Apnoea (OSA) in Sleep Disordered Breathing in the Paediatric Age Group and Assessment of Benefit of Surgery (Tonsillectomy and Adenoidectomy) in Non Responders to Medical Treatment in Mild OSA

Clinical procedures on slight children OSAHS

Effect of oral Xiao-xian decoction combined with acupoint application therapy on pediatric adenoid hypertrophy: A randomized trial

The role of adenoid immune phenotype in polysensitized children with allergic rhinitis and adenoid hypertrophy

Effects of oral cysteine leukotriene receptor antagonist-montelukast on adenoid lymphoid tissue: a histopathological study under light microscope

Evaluation the adenoid and tonsil in children with obstructive sleep apnea hypopnea syndrome

Analysis of Risk Factors for Otitis Media with Effusion in Children with Adenoid Hypertrophy

Adenotonsillectomy Reduces Acute Asthma Exacerbations in Children, Study Shows.